NCT05781048进行中（未招募）1 期
An Open-label, Multi-center Phase I Study of Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 56
- 试验地点
- 1
- 主要终点
- RP2D（Recommended Phase II Dose）
研究概览
简要总结
The study is being conducted to evaluate the efficacy, andsafety of HRS-6209in subjects with advanced solid tumors.To explore the reasonable dosage of HRS-6209.This study also preliminarily evaluated the efficacy of HRS-6209 in patients with advanced solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be willing to participate in the study, sign the informed consent form, have good compliance, and cooperate with follow-up visits.
- •Aged 18-80 years, male or female
- •Patients with advanced malignant tumors confirmed pathologically;
- •Failure of adequate standard treatment, or no effective standard treatment;
- •Patients must have at least 1 extracranial measurable target lesion per RECIST v1.1 ;
- •The expected survival period is more than 12 weeks;
- •The Eastern Cooperative Oncology Group (ECOG) physical fitness score is 0 - 1;
- •Have sufficient bone marrow and organ function (have not received blood transfusion or hematopoietic stimulating factor treatment within 14 days)；
- •Female subjects of childbearing age must undergo a serum pregnancy test within 3 days before starting the study medication, and the result is negative, and are willing to use a medically approved high-efficiency contraception during the study period and within 6 months after the last administration of the study drug Measures: For male subjects whose partners are females of childbearing age, they should be surgically sterilized, or agree to use effective methods of contraception during the study period and within 3 months after the last study administration;
排除标准
- •Subjects with a history of malignant tumors, except patients with cutaneous basal cell carcinoma, superficial bladder cancer, cutaneous squamous cell carcinoma or cervical carcinoma in situ who have undergone possible curative treatment and did not have disease recurrence within 3 years since starting the treatment；
- •Subjects had cancerous meningitis or untreated central nervous system metastases
- •Subjects experienced intestinal obstruction and gastrointestinal perforation within 3 months prior to initial medication
- •There is third-space effusion that cannot be controlled by drainage and other methods (such as massive ascites, pleural effusion, pericardial effusion)；
- •Subjects had clinical cardiac symptoms or disease that was not well controlled within 6 months prior to initial medication
- •Subjects had or currently had idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia , drug pneumonia, or CT during screening showed active pneumonia；
- •Arteriovenous thrombosis occurred within 6 months prior to the first dose
- •Severe infection occurred within 4 weeks prior to initial administration
- •During the screening period/before the first administration, fever of unknown origin> 38.5°C
- •Known history of human immunodeficiency virus (HIV) seropositive status or acquired immunodeficiency syndrome (AIDS)
- •Subjects had active hepatitis；
- •Subjects received live attenuated vaccine within 4 weeks or planned for the study period prior to initial administration；
- •Subjects were scheduled to receive other systemic antitumor therapies during the study period；
- •Participated in other clinical studies within 4 weeks before starting the study drug treatment；
- •Subjects were unable to swallow pills or capsules normally, or had gastrointestinal abnormalities that the researchers determined might affect drug absorption；
- •Other factors as judged by the investigator that may lead to the termination of the study, such as other serious diseases, serious laboratory test abnormalities, or family or social factors that could affect the safety of the subject, or the collection of study data and samples.
研究组 & 干预措施
HRS-6209
Experimental
干预措施: HRS-6209 (Drug)
结局指标
主要结局
RP2D（Recommended Phase II Dose）
时间窗: 4 weeks after treatment initiation
Safety endpoints: Number of subjects with adverse events and the severity of adverse events
时间窗: every 4 weeks after treatment initiation，up to approximately 2 years.
DLT(Dose-limiting toxicity）
时间窗: during the first 30-day cycle of SHR-6209 treatment
MTD（Maximum tolerated dose）
时间窗: 4 weeks after treatment initiation
次要结局
- ORR（Objective response rate (ORR) - RECIST 1.1(Up to approximately 6 months)
- DoR（Duration of Response (DoR)Duration of Response (DoR) per RECIST 1.1）(Up to approximately 2 years)
- DCR（Disease control rate（DCR）-RECIST 1.1(Up to approximately 2 years)
- PFS-Progression-free survival(PFS) PFS per RECIST 1.1(Up to approximately 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid TumorsAdvanced Solid TumorsNCT06598735Jiangsu HengRui Medicine Co., Ltd.290
招募中
1 期
Multicenter Phase I Study of HRS-6208 in Patients With Solid TumorsSolid TumorsNCT06727812Shandong Suncadia Medicine Co., Ltd.206
招募中
1 期
A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer PatientsAdvanced Unresectable or Metastatic Breast CancerNCT06555068Jiangsu HengRui Medicine Co., Ltd.528
招募中
1 期
Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid TumorsAdvanced Solid TumorNCT05765032Suzhou Suncadia Biopharmaceuticals Co., Ltd.120
招募中
1 期
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT05473624Jiangsu HengRui Medicine Co., Ltd.153